Biotech | August 02, 2021
Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
Oxygen Park is a concept where a two-layer layout is being used to plant oxygen releasing trees which releases oxygen for 24 hours
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Subscribe To Our Newsletter & Stay Updated
